ARTIMPLANT INTERIM REPORT JANUARY – SEPTEMBER 2007

Västra Frölunda, Sweden, November 9, 2007

• Net revenue for the third quarter increased to SEK 2.6 million (0.9) and for the first nine months to SEK 11.2 million (3.9)*
• The net loss for the third quarter amounted to SEK 3.6 million (15.9) and for the first nine months to SEK 11.3 million (46.5)
• The net loss for the third quarter, excluding a non-recurring item, amounted to SEK 3.6 million (10.4) and for the first nine months to SEK 9.7 million (29.4)
• Earnings per share, including a non-recurring item, amounted to SEK -0.19 (-0.79)
• Artelon® Tissue Reinforcement was granted clearance in the USA to be marketed for all tendons of the rotator cuff and for four new indications
• Kauko Haapasaari has been employed as head of marketing
• More than 5,000 patients have been treated with Artelon® implants since the launch

EVENTS AFTER THE PERIOD-END
• Biomet's agreement for the rotator cuff application was renegotiated to non-exclusive status
• Biomet has been granted a global, non-exclusive right to market SportMesh™ for four new indications
• Artimplant's obligation to pay future royalties to the inventor of Artelon® was cleared for SEK 2.8 million



This information is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 9, 2007 at 8:45 am.

Artimplant will hold a telephone conference on this report on November 9, 2007 at 11 am. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year